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Abstract
The immunohistochemical detection of the comple-
ment degradation product C4d in renal allograft
biopsies has gained considerable clinical interest in
recent years. The accumulation of C4d along peritubu-
lar capillaries is generally regarded as a marker for an
antibody-mediated allo-response and is associated with
poor graft survival. The aim of this review is to discuss
histological ﬁndings associated with the deposition of
C4d. Emphasis is placed on diagnostic and therapeutic
implications. Unanswered questions regarding C4d and
graft injury are highlighted.
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Background
The gold standard for the diagnosis of rejection and for
guiding patient management is the histological eval-
uation of a renal allograft biopsy [1]. Over the past
decades, morphological criteria of acute and chronic
rejection have been deﬁned, and classiﬁcation schemes
of rejection have been introduced, such as the CCTT
and the Banff schemes [2,3]. They form the backbone
for the clinical decision making, outcome studies and
multicentre analyses of the efﬁcacy of new immuno-
suppressive drugs. However, all current classiﬁcation
schemes of renal allograft rejection have major short-
comings. In particular, the proper identiﬁcation of
humoral rejection episodes after the immediate post-
transplantation period causes problems. The difﬁculties
with identifying humoral rejection are due mainly to the
lack of typical morphological and immunohistochem-
ical changes characterizing different forms of an
antibody response. Hence, antibody-mediated rejection
episodes frequently remained undiagnosed and unclas-
siﬁed. Consequently, nearly all acute rejection episodes
have been classiﬁed as ‘cell mediated’. Tubulo-
interstitial rejection is a prime example [4,5]. This
traditional view currently is under scrutiny. Stimulated
by the pioneering work by Feucht and colleagues from
Munich years ago, C4d has led to major changes in our
understanding of kidney transplant pathology [6–11].
C4d is regarded as an immunohistochemical marker for
a humoral mediated allo-response [10–14]. The trans-
plant centre in Basel has gained experience with C4d
over the last decade. Basel was the ﬁrst transplant
centre in the world which considered C4d to be a very
valuable diagnostic tool and incorporated it into the
diagnostic decision-making process. At present, many
centres use C4d during the work-up of allograft
dysfunction. Major attempts are underway to under-
stand ‘C4d-positive humoral rejection episodes’ better.
Classiﬁcation schemes of renal allograft rejection are
being revised accordingly [15].
C4d is the degradation product of the activated com-
plement factor C4, a component of the classical com-
plement cascade which is typically initiated by binding
of antibodies to speciﬁc target molecules. Following
activation and degradation of the C4 molecule, thio-
ester groups are exposed which allow transient, covalent
binding of the degradation product C4d to endothelial
cell surfaces and extracellular matrix components of
vascular basement membranes near the sites of C4
activation. C4d is also found in intracytoplasmic
vacuoles of endothelial cells [16]. Covalent binding
renders C4d a stable molecule that can easily be detected
by immunohistochemistry (Figure 1; see Appendix for
details of staining protocols). Detection of C4d is
regarded as an indirect sign, a ‘footprint’ of an anti-
body response [10–14,17]. This observation marks a
‘revolution’: for the ﬁrst time, a general and robust
immunohistochemical marker for humoral rejection is
identiﬁed. Since C4d is practically never detected along
peritubular capillaries in the native diseased and
inﬂamed kidney, such as active lupus nephritis,
antineutrophil cytoplasmic antibody (ANCA) disease
or anti-glomerular basement membrane (GBM) disease
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(personal observation), its detection seems ‘transplant
speciﬁc’ [17]. However, it should be kept in mind that
apart from the classical antibody-mediated route of
complement activation, C4 can also be activated via an
alternative, antibody-independent mechanism, the
‘mannan-binding lectin’ pathway [18,19]. Thus, C4d
may also be potentially deposited without prior
antibody binding. Currently, it is unknown whether
this lectin pathway plays any pathophysiological role in
the activation of C4 in renal transplants. Therefore,
based on our current understanding, C4d accumulation
is considered to be a marker for an ‘antibody-mediated
allo-response’. The detection of C4d in a graft biopsy
ideally should be amended by clinical information on
circulating donor-speciﬁc antibodies against major
histocompatibility complex (MHC) class I or class II
[15].
C4d and allo-antibodies
Several lines of evidence clearly support the close link
between C4d and a humoral allo-response deﬁned
by circulating antibodies. Depending on the testing
method used [e.g. crude panel-reactive antibody (PRA)
titre testing vs more sensitive ﬂow cytometry analyses],
antibodies can be detected in 43–90% of C4d-positive
vs 0–50% of C4d-negative patients [11–14,17]. Most
antibodies detected in C4d-positive cases seem donor
speciﬁc (directed against MHC class I and/or class II
antigens). They typically are produced after transplan-
tation, since C4d characteristically is found during the
post-transplantational period [17,20]. Only pre-sensi-
tized high-risk transplant recipients with circulating
antibodies at the time of surgery can show C4d
accumulation immediately after grafting [20]. The
dynamics of the mounted antibody response, comple-
ment activation and degradation seem to be reﬂected by
the rapid turnover of C4d [17]. Based on the location of
the C4d deposits along peritubular capillaries, anti-
bodies are probably directed against peritubular
capillary endothelial antigens. Strong evidence of C4d
as a marker for a humoral response is also provided by
ABO-incompatible transplant recipients, 53% of whom
show C4d deposition in graft biopsies [21,22].
However, many factors remain unknown regarding
antibodies and C4d. For example, are circulating
antibodies not associated with C4d positivity directed
against different antigens and what is their clinico-
pathological signiﬁcance? Is persistent C4d positivity
over weeks or months associated with a persistent
antibody response? How closely does C4d positivity
mirror changes in antibody titres? Do all antibodies
associated with C4d positivity target the same antigens
and do they all have the same clinical signiﬁcance?
Most importantly, is C4d positivity in the absence
of detectable antibodies (10% of patients) due to our
current inability to detect those antibodies, or is C4d
positivity the result of alternative pathways of C4
activation, such as the lectin pathway? Many questions
remain to be answered.
Histological changes
C4d can easily be detected by immunoﬂuorescence
microscopy in frozen material (Figures 1, 2C and 3C)
or by immunohistochemical techniques in formalin-
ﬁxed and parafﬁn-embedded specimens (Figure 3D;
see Appendix for staining protocols). Of diagnostic
relevance is the focal or diffuse, strong accumulation of
C4d along peritubular capillaries in the renal cortex
and/or medulla [11,17]. Immunohistochemistry on
formalin-ﬁxed tissue samples often yields weaker
staining signals. Only non-ﬁbrotic and non-necrotic
parenchymal regions should be evaluated. The minimal
threshold level to call a biopsy ‘positive’ is the detection
of C4d in at least 10 capillaries surrounding adjacent
tubules [17]. C4d deposits in other locations (e.g.
in glomeruli, arterioles with hyalinosis or along atro-
phic tubules) are regarded to be non-diagnostic. It
is important to remember that the accumulation of
C4d marks an independent humoral allo-response.
Consequently, C4d deposits can be detected in combi-
nation with various histological changes (Figure 4). The
association between C4d and morphological signs of
acute ‘cellular’ rejection deﬁned by the CCTT criteria is
statistically signiﬁcant [17]. C4d is found in 24–43% of
type I rejection episodes (i.e. tubulo-interstitial; Figure
2), in 45% of type II rejection (transplant endarteritis),
in 50% of type III rejection (i.e. vascular rejection
with ﬁbrinoid vascular wall necrosis or thrombosis)
and in 50–60% of glomerular rejection (i.e. transplant
glomerulitis or glomerulopathy) [16,17,23]. Tubular
MHC class II (HLA-DR) expression, an immunohis-
tochemical marker of acute rejection [24], is found in
85% of C4d-positive biopsies (Figure 2D; [17]). C4d
positivity can also be detected in combination with
various other histological changes (e.g. interstitial or
arterial vascular sclerosis or even cyclosporin toxicity);
however, these associations do not reach statistical
signiﬁcance [17]. C4d can be seen in 14% of diagnostic
biopsies lacking any morphological evidence of rejec-
tion (even Banff ‘borderline’ changes or polymorpho-
nuclear leukocytes in capillaries), accounting for 13%
of all C4d-positive biopsies in our experience [17].
Fig. 1. Immunoﬂuorecence microscopy shows C4d deposits along
peritubular capillaries (green, arrowheads) and collagen type IV
accumulations along tubular basement membranes (red, arrows). A
tangentially cut glomerulus (G) only shows non-speciﬁc C4d deposits
in mesangial regions. Double incubations performed on fresh frozen
tissue sample, original magniﬁcation 125.
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Less than 5% of our C4d-positive cases present with
so-called ‘acute pure humoral rejection’ (Figure 3):
acute tubular injury, abundant inﬂammatory cells
including polymorphonuclear leukocytes in capillaries,
potentially capillary thrombi or ﬁbrinoid arterial wall
necrosis and clinical signs of severe graft dysfunction.
Evidence of concurrent cellular rejection including
tubular MHC class II upregulation is characteristi-
cally lacking. These cases differ histologically from
‘hyperacute’ rejection since thrombi in large arteries are
uncommon. ‘Acute pure humoral rejection epsiodes’ are
typically seen during the ﬁrst weeks following trans-
plantation, most often in ABO-incompatible trans-
plants [21,22]. C4d has helped with accurately
classifying ‘acute pure humoral rejection’, which is
now categorized speciﬁcally in the most recent revision
of the Banff ‘97 classiﬁcation scheme of renal allograft
rejection [15].
Some authors have suggested a speciﬁc association
between C4d and so-called chronic rejection: sclerosing
transplant vasculopathy, multilayering of peri-tubular
capillary basement membranes and splitting of glo-
merular basement membranes [16,25]. Consequently,
the term ‘chronic humoral rejection’ has been coined
[25]. Unfortunately, the studies to support this concept
are very limited and lack statistical power due to
highly selected case populations. At present, it is
undetermined whether the detection of C4d in these
biopsies really marks a long-lasting ‘chronic’ event or,
alternatively, an active and acute rejection phenom-
enon which is superimposed on sclerosing changes.
Most of the analysed C4d-positive cases in the chronic
rejection category showed well-known morphological
signs of activity, i.e. transplant glomerulitis or
endarteritis [16,25]. Both transplant glomerulitis and
endarteritis are correlated with C4d depositions
[17,23], and they are well-deﬁned forerunner lesions
of chronic rejection [26]. Thus, it seems likely to us
that C4d detection in the setting of ‘chronicity/
sclerosis’ marks an acute/active rejection episode. Such
rejection episodes can respond to anti-rejection
therapy, underscoring the ‘active’ component of
injury [27]. Whether potentially persistent, long-lasting
C4d accumulation/humoral rejection may contribute
Fig. 2. (A–D) Acute, diffuse cellular tubulo-interstitial rejection (Banff type I B), C4d positive. (A and B) The interstitial compartment is
oedematous and shows a diffuse inﬂammatory cell inﬁltrate composed of mononuclear cell elements and plasma cells. There is marked
widespread tubulitis (arrow in B) and tubular injury. Periodic acid–Schiff (PAS)-stained sections; original magniﬁcations 50 (A) and 80
(B). (C) Immunoﬂuorescence microscopy shows bright C4d deposits along peritubular capillaries. Fresh frozen tissue sample; original
magniﬁcation 100. (D) Immunoﬂuorescence microscopy shows MHC class II (HLA-DR) expression in the cytoplasm of tubular epithelial
cells (arrows). Tubular HLA-DR expression is seen typically in cases with cellular rejection and tubulitis. Fresh frozen tissue samples; original
magniﬁcation 100. This biopsy illustrates the concurrence of ‘cellular’ tubulo-interstitial rejection and ‘humoral’ C4d-positive rejection, seen
in 30% of cases in our experience. The biopsy was obtained 3.5 years post-grafting when the serum creatinine levels rose from 150mmol/l
(1.7mg/dl) to 970mmol/l (11mg/dl) due to non-compliance. The patient was treated with a 10 day course of thymoglobulin. Renal function
improved (last follow-up: serum creatinine 265mmol/l, 3.0mg/dl).
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to the development of chronic rejection currently is
undetermined.
Although histological signs of ‘acute/active’ rejection
and, in particular, glomerular rejection (transplant
glomerulitis/glomerulopathy) correlate most signiﬁ-
cantly with C4d accumulation [16,17], it is important
to emphasize that there is no speciﬁc morphological
change deﬁning C4d positivity on light microscopical
grounds. In some instances, pronounced polymorpho-
nuclear leukocytes or mononuclear inﬂammatory cells
in dilated capillaries may indicate a C4d-positive
humoral rejection episode. These changes can be
diagnostically helpful [28]. However, in many trans-
plant biopsies, obvious histological clues suggesting
C4d positivity and/or an antibody response are lacking
[17,23].
Clinical observations and prognosis
During the post-transplantational period, C4d is
detected in 30% of all diagnostic graft biopsies (35%
of all biopsied patients). It is typically seen early after
transplantation (median: 38 days post-grafting).
Fig. 3. (A–D) ‘Pure’ acute humoral rejection without signs of cellular rejection (no upregulation of MHC-class II/HLA-DR in tubules). (A)
Peritubular capillaries contain numerous polymorphonuclear leukocytes (arrows). Focal haemorrhage is seen in the interstitial compartment.
A small artery is unremarkable (asterisk). Glomerular capillaries are occluded due to endothelial cell swelling. Haematoxylin and eosin
(H&E)-stained section; original magniﬁcation 62. (B) A glomerulus shows polymorphonuclear leukocytes and mononuclear cells in
glomerular capillaries (arrows) and intracapillary ﬁbrin thrombi (arrowheads). PAS-stained section; original magniﬁcation 160. (C and D)
Detection of C4d. Immunoﬂuorescence microscopy on frozen tissue (C) and immunohistochemistry on parafﬁn-embedded tissue (D) show
diffuse accumulation of C4d along peritubular capillaries (arrows identify capillary walls in D). (C) Fresh frozen material; original
magniﬁcation 100. (D) Formalin-ﬁxed and parafﬁn-embedded tissue; original magniﬁcation 160. The biopsy was taken on day 6 after
implantation of a cadaveric graft, subsequent to induction therapy with anti-thymoglobulin. At the time of biopsy, urine output had decreased
from 2 to 0.8 l/24 h. Serum creatinine levels had increased within 2 days from 300mmol/l (3.4mg/dl on day 4) to 530mmol/l (6mg/dl on day 6).
Antibody screening showed 60% anti-HLA antibodies and 28% anti-A2. The patient was treated with ﬁve courses of plasmapheresis and a 10
day course of thymoglobulin. Renal function deteriorated and a graft nephrectomy had to be performed 16 days post-surgery, revealing
combined cellular rejection (very severe transplant endarteritis, type IIB) and persistent humoral rejection (diffuse C4d positivity) with infarcts
(nephrectomy ﬁndings not shown).
Fig. 4. Histological changes and the detection of C4d along
peritubular capillaries. In renal allograft biopsies, C4d can be
detected in association with different histological changes and even
in the setting of normal histology. Statistical signiﬁcant is the
correlation between C4d and ‘acute cellular rejection’, in particular
transplant glomerulitis. Only a minority of C4d-positive biopsies
represent ‘pure humoral rejection’.
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Occasionally, C4d can also be detected years after
grafting (in our experience, as late as 15 years). C4d is a
dynamic marker since it can accumulate and disappear
within days (4–8 days). Occasionally, C4d is detected
persistently over many months [17].
At present, the clinical signiﬁcance of C4d deposits in
renal allografts is incompletely understood (Table 1).
As a general rule, C4d positivity in the setting of
cellular rejection or signiﬁcant allograft dysfunction (in
our experience, serum creatinine levels >200 mmol/l,
2.3mg/dl) indicates serious rejection episodes requiring
aggressive treatment [9,17,23,29]. Often, long-term
prognosis is poor. Feucht et al. initially reported an
overall 12 month graft failure rate of 40% in C4d-
positive cases, in contrast to only 10% in C4d-negative
controls [9]. C4d was found to be the strongest
independent predictor of poor graft outcome [11,23].
The survival rates of C4d-positive tubulo-interstitial
(Banff type I) and vascular (transplant endarteritis,
Banff type II) acute rejection episodes are poor when
compared with corresponding C4d-negative controls.
In contrast, the clinical signiﬁcance of C4d positivity
in grafts with only mild dysfunction (in our experience,
serum creatinine levels <155mol/l, 1.75mg/dl) and
without morphological signs of rejection is unclear. We
have made this observation in 15% of C4d-positive
cases [17]. Approximately 3% of surveillance protocol
biopsies taken from stable grafts without subclinical
‘cellular’ rejection are C4d positive [30]. The long-
term outcome of these transplants appears favourable,
and patients do not seem to beneﬁt from immediate
anti-rejection therapy [17]. Very little is known about
continuous C4d deposition in stable grafts over a
period of many months. Such extended accumulation
of C4d can be seen in surveillance biopsies taken from
well functioning transplants subsequent to successfully
treated C4d-positive rejection episodes (personal
observation). C4d has also been detected in stable
grafts following the successful transplantation across
ABO barriers [22]. Whether these ﬁndings potentially
indicate ‘subclinical humoral rejection’ with detrimen-
tal effects on long-term graft survival or, alternatively,
represent ‘accommodation’ remains to be determined in
future studies [31].
Treatment (Figure 5)
Treatment strategies to manage C4d-positive humoral
rejection episodes currently are poorly deﬁned. Some
encouraging therapeutic attempts have been reported
with different protocols, either alone or in combination.
Those include high dose tacrolimus and mycophenolate
mofetil, immunoabsorption, plasmapheresis, i.v. immu-
noglobulin or anti-lymphocytic preparations, which
are often given in cases of concurrent cellular rejection
[27,29,32–34]. Response to therapy appears to be poor
if thrombi are identiﬁed. At present, case numbers are
too low to render general therapeutic recommenda-
tions.
The transplant centre in Basel, Switzerland tradi-
tionally has regarded C4d positivity as an indicator
for clinically severe rejection episodes (i.e. transplant
endarteritis). In most cases, as an immediate response,
anti-lymphocytic preparations (i.e. ATG or OKT3) had
been administered, especially for C4d-positive tubulo-
interstitial rejection episodes and cases of transplant
glomerulitis. In our opinion, this therapeutic approach
explains the favourable and unique Basel outcome data:
neither allograft function nor 1 year graft survival
differed signiﬁcantly between C4d-positive and corre-
sponding C4d-negative groups [17]. Thus, aggressive
treatment with anti-lymphocytic preparations may be a
practical strategy to manage at least some C4d-positive
rejection episodes. Since the Basel data were collected
retrospectively and represent the experience of only a
single centre, prospective multicentre studies are needed
for further validation.
C4d positivity in the setting of normal or only
minimally altered allograft function and ‘normal’
histology is poorly understood. Preliminary data
suggest that C4d accumulation under these conditions
does not indicate poor outcome and patients do not
seem to beneﬁt from immediate anti-rejection therapy
[17,30,31].
C4d in other solid organ grafts
Little is known currently about C4d accumulation in
other solid organ allografts. Preliminary data suggest
that heart allografts are comparable with kidney
transplants [35,36]. C4d was found in early post-
transplant endomyocardial biopsies and was associated
with poor graft survival [37]. In dysfunctioning lung
transplants, C4d could be detected in septal capillaries
[38]. C4d has also been found in liver allografts carrying
a diagnosis of antibody-mediated rejection [39].
Table 1. Different forms of humoral responses seen in kidney
transplants/transplant recipients
Graft Antibodies C4d Morphological
dysfunction (donor speciﬁc) changes
Form I No Yes No No
Form IIa No Yes Yes No
Form IIIb No Yes Yes Yes
Form IVc Yes Yes Yes Yes
aThese cases potentially represent subclinical pure humoral rejection
or accommodation.
bMost of these cases probably represent subclinical rejection, often
humoral and cellular.
cForm IV represents cases of humoral rejection, either in the acute
pure form or in combination with cellular rejection, chronic
sclerosing changes or other alterations.
These forms of humoral responses are descriptive in nature; they do
not deﬁne treatment groups. Adapted from the NIH-sponsored
‘Consensus conference to analyze humoral rejection in solid organ
transplantation’, Bethesda, MD, April 23–24, 2003.
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Future perspective
A major change of our philosophy explaining renal
allograft dysfunction currently is occurring. C4d has
‘magically’ enabled us to detect humoral mediated allo-
responses in histological sections and to re-focus our
attention on antibody-induced graft injury. Thus, C4d
seems indeed to be a ‘magic’ marker. We have learned
that humoral mediators of rejection are not limited to
rare forms of hyperacute rejection episodes. Rather,
humoral and cellular rejection episodes often concur.
At present, most of these humoral mediators (poten-
tially antibodies directed against MHC class I and/or
class II antigens) and their direct impact on patient
management and graft survival are poorly understood.
Future research should address several issues. First and
foremost, we need to clarify whether the accumulation
of C4d is always initiated by the deposition of allo-
antibodies or whether alternative pathways, such as the
lectin pathway, may be involved. What antibodies lead
to activation of C4 along peritubular capillaries and are
all of these antibodies clinically relevant? Of utmost
practical signiﬁcance are two questions: (i) what is the
signiﬁcance of C4d deposits in stable grafts with normal
histology; and (ii) is persistent C4d accumulations over
months pathophysiologically important? We must
deﬁne treatment strategies in order to manage C4d-
positive rejection episodes better. In the spring of 2003,
the NIH (National Institute of Health, USA) speciﬁ-
cally addressed some of these questions during an
expert panel meeting which focused exclusively on
humoral rejection and C4d accumulation.
Since many aspects regarding C4d and antibodies
remain to be determined in upcoming studies, it seems
premature to introduce new classiﬁcation schemes of
humoral rejection at present. Therefore, we, the
authors, currently rather recommend to report C4d
staining results in pathology reports as ‘qualiﬁers’,
amending traditional, histology-based diagnostic
categories [40]. Thus, for example, tubulo-interstitial
rejection, transplant endarteritis or glomerulitis can
be ‘C4d positive’ or ‘C4d negative’. In addition, we
recognize rare forms of pure, C4d-positive acute
humoral rejection episodes characterized by polymor-
phonuclear leukocytes and thrombi. This approach
ensures an adequate clinico-pathological correlation at
the present time. Conventional diagnostic categories
remain unaltered, facilitating future multicentre com-
parative trials.
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Appendix
Detection of C4d
The complement degradation product C4d can be
detected easily in fresh frozen tissue samples by immu-
noﬂuorescence microscopy. We use a mouse mono-
clonal antibody which is commercially available from
Quidel (San Diego, CA) according to a previously
published protocol [17].
C4d can also be detected in formalin-ﬁxed and
parafﬁn-embedded tissue sections employing a rabbit
polyclonal antibody (Biomedica Gruppe, Vienna,
Austria). We use the steam antigen retrieval technique
(30min), followed by a 30min incubation with the
primary antibody at 37C (dilution 1:50) and subse-
quent avidin/biotin histochemical staining procedures.
Detection of tubular MHC class II (HLA-DR)
expression
The upregulation of MHC class II in tubular cells
is evaluated by direct immunoﬂuorescence microscopy
on frozen tissue samples using a ﬂuorescein isothio-
cyanate-conjugated mouse anti-human monoclonal
antibody (DAKO A/S, Glostrup, Denmark; dilution
1:40; 30min incubation at room temperature).
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